Agomab Therapeutics NV

Company snapshot

Chemomab (Nasdaq: CMMB) is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed nebokitug (CM-101), a first-in-class dual activity monoclonal antibody that neutralizes CCL24 and has demonstrated disease-modifying

• 6 active pipeline program(s) linked via ClinicalTrials.gov.
• 4 US patent(s) indexed to this assignee profile.
• 6 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Agomab Therapeutics NV. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Agomab Therapeutics NV.

1. Jun 8, 2026 Clinical update

   AGMB129-01-CL-109 — Phase 1

2. Jun 8, 2026 Clinical update

   AGMB101-01-CL-102 — Phase 1

3. May 23, 2026 Clinical update

   AGMB-129 — Phase 2

4. May 23, 2026 Clinical update

   AGMB-129 — Phase 1

5. May 23, 2026 Clinical update

   AGMB-447 — Phase 1

View all clinical trial activity →

• What is Agomab Therapeutics NV?

  Agomab Therapeutics NV is a biotech organization headquartered in Tel Aviv, USA. It trades on NYSE under ticker AGMB. Primary therapeutic focus areas include Fibrostenotic Crohn’s disease, liver cirrhosis, Fibrostenotic Crohn's Disease. NovaPharmaNews links 6 clinical program(s),

• Is Agomab Therapeutics NV publicly traded?

  Yes. Agomab Therapeutics NV is listed with ticker AGMB on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Agomab Therapeutics NV develop or market?

  We link 2 drug profile(s) where Agomab Therapeutics NV is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/agomab-therapeutics-nv#company-drugs.

• What are the latest developments for Agomab Therapeutics NV?

  In the last 12 months our linked public records show 6 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Agomab Therapeutics NV focus on?

  Agomab Therapeutics NV focuses on Fibrostenotic Crohn’s disease, liver cirrhosis, Fibrostenotic Crohn's Disease based on our analysis of their pipeline programs and drug development activities.